Treatment of pulmonary disease caused by opportunist mycobacteria.
- 1 June 1989
- Vol. 44 (6) , 449-454
- https://doi.org/10.1136/thx.44.6.449
Abstract
Opportunist mycobacterial infections localised to the chest may be treated with combinations of standard antimycobacterial drugs. The combination of rifampicin and ethambutol seems to be particularly effective, both in vivo and in vitro. In vitro sensitivity testing with single drugs may have a role in the future when the levels of in vitro resistance compatible with the clinical response to treatment are eventually established. Sensitivity testing against drugs in combination may prove useful for modifying treatment regimens in those patients who either fail to respond to initial chemotherapy or relapse. Further evidence on this will, it is hoped, emerge from the prospective studies currently in progress.Keywords
This publication has 69 references indexed in Scilit:
- Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.Thorax, 1987
- Synergistic effects of antimycobacterial drag combinations onMycobacterium avium complex determined radiometrically in liquid mediumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Pulmonary infection with mycobacterium malmoense—A review of treatment and responseTubercle, 1985
- Long-term Results of Pulmonary Resection for Atypical Mycobacterial DiseaseThe Annals of Thoracic Surgery, 1983
- Selecting Drug Combinations for Treatment of Drug‐Resistant Mycobacterial DiseasesThe Journal of Clinical Pharmacology, 1982
- A system for the examination of tubercle bacilli and other mycobacteriaTubercle, 1976
- The pattern of resistance development to rifampicin in mycobacterium tuberculosisTubercle, 1972
- Surgical Treatment of Pulmonary Disease Due to Mycobacterium kansasiiThe Annals of Thoracic Surgery, 1971
- Treatment of unclassified mycobacterial infection of the lungsThorax, 1968
- Unclassified Mycobacterial DiseasesAnnual Review of Medicine, 1966